CU23204A1 - Combinaciones de factores reguladores del crecimiento y hormonas para el tratamiento de neoplasias - Google Patents

Combinaciones de factores reguladores del crecimiento y hormonas para el tratamiento de neoplasias

Info

Publication number
CU23204A1
CU23204A1 CU20020338A CU20020338A CU23204A1 CU 23204 A1 CU23204 A1 CU 23204A1 CU 20020338 A CU20020338 A CU 20020338A CU 20020338 A CU20020338 A CU 20020338A CU 23204 A1 CU23204 A1 CU 23204A1
Authority
CU
Cuba
Prior art keywords
hormones
growth
regulatory factors
neoplasias
combinations
Prior art date
Application number
CU20020338A
Other languages
English (en)
Inventor
Santiago Glay Chinea
Saez Yovisleidys Lopez
Dominguez Hector Hernandez
Aguilera Lesvia Calzada
More Niurka Arteaga
Aguilar Franklin Fuentes
Barranco Jesus Junco
Fuentes Eddy Bover
Nieto Gerardo Enrique Guillen
Baker Roberto Basulto
Vazquez Eulogio Pimentel
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Priority to CU20020338A priority Critical patent/CU23204A1/es
Priority to MXPA05006979A priority patent/MXPA05006979A/es
Priority to ES03767380T priority patent/ES2334344T3/es
Priority to CA2507470A priority patent/CA2507470C/en
Priority to PCT/CU2003/000019 priority patent/WO2004058297A1/es
Priority to RU2005123813/13A priority patent/RU2321422C2/ru
Priority to AU2003291915A priority patent/AU2003291915B2/en
Priority to AT03767380T priority patent/ATE445410T1/de
Priority to DE60329710T priority patent/DE60329710D1/de
Priority to US10/539,172 priority patent/US20060193853A1/en
Priority to KR1020057009823A priority patent/KR100712426B1/ko
Priority to CN2003801075594A priority patent/CN1732017B/zh
Priority to JP2004562478A priority patent/JP4384054B2/ja
Priority to EP03767380A priority patent/EP1576965B1/en
Priority to BR0317506-5A priority patent/BR0317506A/pt
Priority to MYPI20034978A priority patent/MY140305A/en
Priority to ZA200504820A priority patent/ZA200504820B/en
Publication of CU23204A1 publication Critical patent/CU23204A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A61K39/001131—Epidermal growth factor [EGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A61K39/001134—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A61K39/001135—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Silicon Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invencion se refiere al campo de la inmunología, la endocrinología y la oncología, y en particular se basa en la generacion de respuesta inmune, de forma combinada, hacia determinados factores de crecimiento y hormonas. Un efecto sinÉrgico entre factores reguladores del crecimiento (EGF, TGF,VEGF) y de hormonas involucradas en la cascada de liberacion de hormonas sexuales, o de la reproduccion: (GnRH, LH, FSH), descubierta aquí potencia la respuesta antitumoral, expresada como reduccion de la masa tumoral y un aumento del tiempo de supervivencia.
CU20020338A 2002-12-27 2002-12-27 Combinaciones de factores reguladores del crecimiento y hormonas para el tratamiento de neoplasias CU23204A1 (es)

Priority Applications (17)

Application Number Priority Date Filing Date Title
CU20020338A CU23204A1 (es) 2002-12-27 2002-12-27 Combinaciones de factores reguladores del crecimiento y hormonas para el tratamiento de neoplasias
MXPA05006979A MXPA05006979A (es) 2002-12-27 2003-12-22 Combinaciones de factores reguladores del crecimiento y hormonas para el tratamiento de neoplasias.
ES03767380T ES2334344T3 (es) 2002-12-27 2003-12-22 Combinaciones de factores reguladores del crecimiento y de hormonas para el tratamiento de las neoplasias.
CA2507470A CA2507470C (en) 2002-12-27 2003-12-22 Combinations of growth regulating factors and hormones for the treatment of neoplasia
PCT/CU2003/000019 WO2004058297A1 (es) 2002-12-27 2003-12-22 Combinaciones de factores reguladores del crecimiento y hormonas para el tratamiento de neoplasias
RU2005123813/13A RU2321422C2 (ru) 2002-12-27 2003-12-22 Комбинации регулирующих рост факторов и гормонов для лечения неоплазии
AU2003291915A AU2003291915B2 (en) 2002-12-27 2003-12-22 Combinations of growth regulating factors and hormones for the treatment of neoplasia
AT03767380T ATE445410T1 (de) 2002-12-27 2003-12-22 Kombinationen wachstums- und hormonsteuernder faktoren für die behandlung von neoplasie
DE60329710T DE60329710D1 (de) 2002-12-27 2003-12-22 Kombinationen wachstums- und hormonsteuernder faktoren für die behandlung von neoplasie
US10/539,172 US20060193853A1 (en) 2002-12-27 2003-12-22 Combinations of growth-and hormone-regulating factors for the treatment of neoplasia
KR1020057009823A KR100712426B1 (ko) 2002-12-27 2003-12-22 종양형성의 치료를 위한 성장제어 인자 및 호르몬의 조합
CN2003801075594A CN1732017B (zh) 2002-12-27 2003-12-22 用于治疗瘤形成的生长调节因子和激素的组合
JP2004562478A JP4384054B2 (ja) 2002-12-27 2003-12-22 新生物形成の処置のための増殖調節因子及びホルモンの組合せ
EP03767380A EP1576965B1 (en) 2002-12-27 2003-12-22 Combinations of growth- and hormone-regulating factors for the treatment of neoplasia
BR0317506-5A BR0317506A (pt) 2002-12-27 2003-12-22 Combinações farmacêuticas para o tratamento de neoplasias mediante administração simultânea, e, método para a geração de resposta imune combinada
MYPI20034978A MY140305A (en) 2002-12-27 2003-12-24 Combination of growth regulator factors with hormones for neoplasia treatment
ZA200504820A ZA200504820B (en) 2002-12-27 2006-01-16 Combinations of growth regulaitng factors and hormones for the treatment of neoplasia

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20020338A CU23204A1 (es) 2002-12-27 2002-12-27 Combinaciones de factores reguladores del crecimiento y hormonas para el tratamiento de neoplasias

Publications (1)

Publication Number Publication Date
CU23204A1 true CU23204A1 (es) 2007-05-18

Family

ID=40091671

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20020338A CU23204A1 (es) 2002-12-27 2002-12-27 Combinaciones de factores reguladores del crecimiento y hormonas para el tratamiento de neoplasias

Country Status (17)

Country Link
US (1) US20060193853A1 (es)
EP (1) EP1576965B1 (es)
JP (1) JP4384054B2 (es)
KR (1) KR100712426B1 (es)
CN (1) CN1732017B (es)
AT (1) ATE445410T1 (es)
AU (1) AU2003291915B2 (es)
BR (1) BR0317506A (es)
CA (1) CA2507470C (es)
CU (1) CU23204A1 (es)
DE (1) DE60329710D1 (es)
ES (1) ES2334344T3 (es)
MX (1) MXPA05006979A (es)
MY (1) MY140305A (es)
RU (1) RU2321422C2 (es)
WO (1) WO2004058297A1 (es)
ZA (1) ZA200504820B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8163283B2 (en) * 2009-09-03 2012-04-24 Vancouver Biotech Ltd. Monoclonal antibodies against gonadotropin-releasing hormone receptor
CN103068850A (zh) * 2010-05-26 2013-04-24 明尼苏达大学评议会 单链可变片段抗-cd133抗体及其用途
CN104004762B (zh) * 2014-05-20 2016-03-30 南京医科大学附属南京儿童医院 Tgf-r反义序列及其在制备抗气道炎症反应药物中的应用
EA201991738A1 (ru) * 2017-01-20 2020-02-11 Имьюн Систем Регулеишн Холдинг Аб Новые соединения (иммунорелины)
BR112019028280A2 (pt) 2017-07-04 2020-07-14 Curevac Ag moléculas de ácido nucleico
KR20220062080A (ko) * 2019-09-12 2022-05-13 헥사머 테라퓨틱스, 인코포레이티드 전립선암 치료를 위한 면역요법
WO2025088088A1 (en) 2023-10-27 2025-05-01 CureVac SE Rna composition for improving cell therapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2228262B (en) * 1989-01-25 1992-10-07 Nat Inst Immunology Antigenic derivative of gnrh
US5211952A (en) * 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
EP0666868B2 (en) * 1992-10-28 2006-06-14 Genentech, Inc. Use of anti-VEGF antibodies for the treatment of cancer
CA2261433A1 (en) * 1993-12-09 1995-06-10 Belinda Sanchez Ramirez Composition comprising autologous epidermal growth factor
CU22627A1 (es) * 1996-12-17 2000-12-22 Ct Ingenieria Genetica Biotech Preparado vacunal para la inmuno-castración reversible de mamíferos
CU23077A1 (es) * 2000-12-06 2005-08-17 Centro Inmunologia Molecular Composicion vacunal que contiene factor de crecimiento transformante (tgf-alfa). su uso en la terapia de enfermedades malignas
US8026229B2 (en) * 2001-08-13 2011-09-27 Sterix Limited Antitumor-active 2-alkoxyestradiol sulfamates

Also Published As

Publication number Publication date
CA2507470C (en) 2010-11-09
BR0317506A (pt) 2005-11-16
KR20050089016A (ko) 2005-09-07
EP1576965B1 (en) 2009-10-14
DE60329710D1 (de) 2009-11-26
CN1732017B (zh) 2011-12-21
MXPA05006979A (es) 2005-08-16
WO2004058297A1 (es) 2004-07-15
US20060193853A1 (en) 2006-08-31
JP4384054B2 (ja) 2009-12-16
CA2507470A1 (en) 2004-07-15
AU2003291915A1 (en) 2004-07-22
AU2003291915B2 (en) 2008-12-04
KR100712426B1 (ko) 2007-04-27
EP1576965A1 (en) 2005-09-21
ATE445410T1 (de) 2009-10-15
CN1732017A (zh) 2006-02-08
RU2321422C2 (ru) 2008-04-10
ZA200504820B (en) 2006-03-29
RU2005123813A (ru) 2006-01-27
JP2006514036A (ja) 2006-04-27
ES2334344T3 (es) 2010-03-09
MY140305A (en) 2009-12-31

Similar Documents

Publication Publication Date Title
MX2019004775A (es) Anticuerpos anti antigeno 4 del linfocito t citotoxico (ctla-4) activables y sus usos.
DK1824489T3 (da) Stereoisomerisk berigede 3-arminocarbonyl-bicyclohepten-pyrimidinamin-forbindelser og anvendelse deraf
PH12020551427A1 (en) Epinephrine spray formulations
MX2022003184A (es) Variantes del cnp y sus conjugados.
TWD164754S (zh) 可攜式無線播放器之部份
CL2021001260A1 (es) Anticuerpos anti-sirpa humanizados
CU23204A1 (es) Combinaciones de factores reguladores del crecimiento y hormonas para el tratamiento de neoplasias
MX373448B (es) Composiciones útiles en el tratamiento de síntomas del tracto urinario inferior, hiperplasia prostática benigna, disfunción eréctil.
SA519410324B1 (ar) صياغات رش إيبينيفرين
MX377781B (es) Composiciones y metodos para diagnostico y tratamiento del cancer.
TWD201849S (zh) 行動電話
UY38800A (es) Receptor de antígeno quimérico (car) anti-hk2
MX2024002069A (es) Anticuerpos anti-hla-g.
AR119271A1 (es) Administración del vector viral adenoasociado para el tratamiento de enfermedades mediadas por la calicreína plasmática desregulada
MX2023011202A (es) Agonistas de receptores alfa de ácido retinoico (rara) para el tratamiento de leucemia mieloide aguda (aml) y síndrome mielodisplásico (mds).
PH12020551994A1 (en) Tlr7 agonists
MX2023005591A (es) Metodos de tratamiento de enfermedades y trastornos.
PH12021550033A1 (en) Tumor reduction formulations and methods of use thereof
MX2022011845A (es) Terapia combinada con un inhibidor de idh mutante y un inhibidor de bcl-2.
MX2020002585A (es) Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer.
MX2019013096A (es) Peptidos para el tratamiento de diabetes.
PH12021550376A1 (en) Combination therapy
MX2020006533A (es) Inhibidores del receptor activado por proteasa-2.
MX2021005386A (es) Fragmentos de peptidos para tratamiento de diabetes.
MX2021000314A (es) Formulaciones reductoras de tumores y metodos de uso de las mismas.

Legal Events

Date Code Title Description
FD Lapse (for not paying fees)